Aura Biosciences Advances Clinical Trials Amid Enrollment Challenges

Aura Biosciences is advancing its clinical trials for early choroidal melanoma and non-muscle invasive bladder cancer. Enrollment challenges have been addressed through measures implemented in 2025. The biotechnology company operates in the precision immunotherapy sector for solid tumors, with a market capitalization of approximately $346.63 million. Aura Biosciences reports no revenue, with a current ratio of 12.39 and a quick ratio of 12.39. Despite a Piotroski F-Score of 1, indicating poor business operations, institutional ownership is high at 81.62%.